Transplantation: rituximab induction for prevention of HLA-antibody rebound

Puneet Sood; Sundaram Hariharan

doi:10.1038/nrneph.2014.179

Transplantation: rituximab induction for prevention of HLA-antibody rebound

Nat Rev Nephrol. 2014 Dec;10(12):682-3. doi: 10.1038/nrneph.2014.179. Epub 2014 Oct 7.

Authors

Puneet Sood¹, Sundaram Hariharan¹

Affiliation

¹ Department of Medicine and Department of Transplant Surgery, University of Pittsburgh Medical Center, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA.

PMID: 25287429
DOI: 10.1038/nrneph.2014.179

Abstract

Desensitization therapy enables HLA-incompatible transplantation. However, desensitized patients have an increased risk of antibody-mediated rejection, and the presence of donor-specific antibodies (DSAs) is associated with poor outcomes. A new study has assessed the effect of rituximab induction on DSA production in kidney transplant recipients with high immunological risk.

Publication types

Comparative Study

MeSH terms

Antibodies, Monoclonal, Murine-Derived / administration & dosage*
Case-Control Studies
Desensitization, Immunologic / methods
Female
Graft Rejection / prevention & control*
Graft Survival
HLA Antigens / drug effects*
HLA Antigens / immunology
Humans
Kidney Transplantation / adverse effects
Kidney Transplantation / methods*
Living Donors
Male
Prognosis
Retrospective Studies
Risk Assessment
Rituximab
Transplantation Immunology / drug effects*
Treatment Outcome

Substances

Antibodies, Monoclonal, Murine-Derived
HLA Antigens
Rituximab